Download Targeting device for high precision radiation theraphy of prostate

• Requires little or no doctor’s time
• No surgical procedure
• Safe method with 5 years follow-up studies
• Well tolerated among patients
• Fast (no need to wait 1-2 weeks)
References:
1. Per Fransson et al. “five-year prospective patient evaluation of bladder and bowel symptoms
after dose escalated radiotherapy for prostate cancer with the beamcath® technique”, Int. J.
Radiation Oncology Biol. Phys., 2006. 66(2). 430-438.
2. Hans C. J. De Boer et al., “Application of the no action level (nal) protocol to correct for prostate motion based on electronic portal imaging of implanted markers”, Int. J. Radiation Oncology
Biol. Phys., 2005, 61(4), 969–983.
3. Alan Pollack et al., “Prostate cancer radiation dose response: results of the M. D. Anderson
phase III randomized trial”, Int. J. Radiation Oncology Biol. Phys., 2002, 53(5), 1097–1105.
Targeting device for high precision radiation theraphy
of prostate cancer.
Beampoint AB · Kista Science Tower. SE-164 51 Kista, Sweden
Phone: +46 8 751 01 75 Fax: +46 8 35 00 83
www.beampoint .se
• The prostate can be better targeted for high precision radiotherapy
• Reduction in side-effects to adjacent organs, allowing higher doses to
be delivered
Maximises precision during treatment of prostate cancer
thus allowing for higher radiation dosage.
IMPROVED OUTCOME WITH
HIGHER DOSAGE
BeamCath® is a device to assist in dose escalation, using conventional, conformal radiation
therapy techniques.
It has been shown that the outcome for prostate cancer patients is improved when they are
given higher doses of radiation (Hanks 1999,
Pollack 2000). Increased radiation dose however causes greater risk of side-effects, particularly in the rectum and bladder. Accordingly,
the radiation must be focused to the prostate
also taking into account the variations in target
position.
BETTER CONTROL–FEWER SIDE EFFECTS
BeamCath®, is a tool for visualising the prostate position during treatment of prostate cancer,
with external beam conformal radiation therapy
technique.
Introducing a catheter with fiducial markers into
the urethra, for planning, simulation and boost-
treatment dose escalation with high precision
avoiding complications in sensitive organs and
tissues adjacent to the prostate.
• High density fiducial markers provide a reference system for planning,
simulation and treatment
The BeamCath® method allows for exact positioning of the external
beam boost during radiation therapy
COST-EFFECTIVE
Increasing the external beam radiation dose is
a costeffective method to dose-escalate prostate cancer treatment, since regular treatment machines and portal imaging systems are
used. Total cost is significantly lower than for
other, invasive methods that are more labourintensive and might require large investments in
new equipment.
PROVEN RESULTS
Since 1997 more than 1 500 prostate cancer
patients have been treated with dose escalation
up to 78 Gy with BeamCath®. The BeamCath®
catheter technique has been a prerequisite to
do this without any increase in side-effects in
the bladder and rectum.
Lumen for air-inflation to the
balloon which keeps the catheter cuff in the bladder
Cuff (balloon)
High density fiducial markers
• Straightforward technique easily incorporated into existing treatment
protocols and clinical practices
Connection for inflating the cuff.
Connection for instillation of
contrast into the bladder
BLADDER
PROSTATE
The catheter is introduced into the urethra and retained by inflating the balloon in the bladder. A light constant pull is applied to the catheter, to ensure it is in
the same position for all phases of the therapy-planning, simulation and the initial target movement.
The markers within the catheter are the size of lead
shot and are made of very high-density material so
as to be visible during all treatment phases. Utilising portal imaging for beam alignment, the catheter
markers help doctors target the desired treatment
area. It is possible to make adjustments for gland
movement immediately before treatment is given.
TUMOUR